Canaccord Genuity Maintains Buy on Merus, Maintains $67 Price Target
$MRUS
Biotechnology: Pharmaceutical Preparations
Health Care
Canaccord Genuity analyst John Newman maintains Merus (NASDAQ:MRUS) with a Buy and maintains $67 price target.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/24/2024 | $72.00 | Buy | UBS |
| 3/28/2024 | $69.00 | Buy | Truist |
| 3/4/2024 | $42.00 → $65.00 | Buy | Needham |
| 11/2/2023 | $45.00 | Buy | Canaccord Genuity |
| 8/21/2023 | Outperform | TD Cowen | |
| 8/2/2022 | $38.00 | Buy | Stifel |
| 2/11/2022 | $45.00 | Outperform | BMO Capital |
| 2/10/2022 | $45.00 | Buy | Needham |
Canaccord Genuity analyst John Newman maintains Merus (NASDAQ:MRUS) with a Buy and maintains $67 price target.
8-K - Merus N.V. (0001651311) (Filer)
10-Q - Merus N.V. (0001651311) (Filer)
10-Q - Merus N.V. (0001651311) (Filer)
SC 13G/A - Merus N.V. (0001651311) (Subject)
SC 13G - Merus N.V. (0001651311) (Subject)
SC 13G/A - Merus N.V. (0001651311) (Subject)
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the United States Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for zenocutuzumab (Zeno) Biologics License Application (BLA) currently under priority review. The US FDA has extended the PDUFA goal date to February 4, 2025 to enable sufficient time to review information recently submitted by the Company in response to a CMC information request. No addition
Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling Petosemtamab in 2L+ r/m HNSCC interim clinical data accepted for rapid oral presentation at ESMO® Asia Congress 2024 Based on the Company's current operating plan, existing cash, cash equivalents, and marketable securities expected to fund Merus' operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the first patient has been dosed in the Company's phase 3 trial evaluating the efficacy and safety of petosemtamab, a Biclonics® targeting EGFR and LGR5, in combination with pembrolizumab, compared to pembrolizumab as first line (1L) therapy for patients with PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC), referred to as the LiGeR-HN1 trial. Merus has confirmed through feedback
UBS initiated coverage of Merus with a rating of Buy and set a new price target of $72.00
Truist initiated coverage of Merus with a rating of Buy and set a new price target of $69.00
Needham reiterated coverage of Merus with a rating of Buy and set a new price target of $65.00 from $42.00 previously
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Fabian Zohren M.D., PhD as Chief Medical Officer (CMO) effective July 1, 2024. Andrew Joe, M.D. will step down from the CMO role and continue to serve as a Consultant for the next three months. In addition, effective July 1, Hui Liu, Ph.D., EVP, Chief Business Officer & Head of Merus U.S. is leaving Merus. The Company has initiated a search to find a replacement to head the business development f
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Greg Perry as the Company's Chief Financial Officer (CFO). Additionally, Greg has been designated as the Company's principal financial officer, succeeding Bill Lundberg, M.D., in such role. In connection with his appointment as the Company's Chief Financial Officer, on June 14, 2023, Greg resigned from the Company's Board of Directors. "I am excited to welcome Greg as our CFO and look forward to drawing from his broad biotech e
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a range of specialty markets, including oncology. "Shannon will be instrumental in advancing Merus' mission to become a commercial-stage company, further advancing the strategy for our lead clinical progr
4 - Merus N.V. (0001651311) (Issuer)
4 - Merus N.V. (0001651311) (Issuer)
3 - Merus N.V. (0001651311) (Issuer)
Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling Petosemtamab in 2L+ r/m HNSCC interim clinical data accepted for rapid oral presentation at ESMO® Asia Congress 2024 Based on the Company's current operating plan, existing cash, cash equivalents, and marketable securities expected to fund Merus' operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today
67% response rate observed among 24 evaluable patients Conference Call on Tuesday, May 28th at 8 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced interim clinical data as of a March 6, 2024 data cutoff from the ongoing phase 1/2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab. These data will be presented by Dr. Jerome Fayette M.D. Ph.D., Centre Léon Bérard, Lyon, France at the 2024 American Society of Clinical Oncology® (
- 60% response rate observed among 10 evaluable patients - Favorable safety profile in 26 patients enrolled as of the abstract cutoff date, with no significant overlapping toxicities observed - Conference call on Tuesday, May 28 at 8:00 a.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of an abstract regarding petosemtamab in combination with pembrolizumab on the 2024 American Society of Clinical Oncol